Top Markets
#1 MowCat MowCat +26.51%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +17.74%
#3 Versatize Coin Versatize Coin +16.66%
#4 QuantixAI QuantixAI +14.43%
#5 Pons Pons +13.72%
#6 OriginTrail OriginTrail +13.50%
#7 Wrapped NXM Wrapped NXM +10.25%
#8 Collector Crypt Collector Crypt +8.37%
#9 Siren Siren +8.14%
#10 DAPPOS DAPPOS +7.09%
Coin of the day
MowCat MowCat
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc.

NGM
Classement en actions #20914
NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering... NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently undergoing Phase IIb clinical evaluation for non-alcoholic steatohepatitis (NASH). Another key asset, MK-3655, is an agonistic antibody designed to activate fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb trials for treating both type 2 diabetes and NASH. NGM's pipeline further encompasses NGM120, an antagonist antibody targeting GFRAL, in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II development for geographic atrophy; and NGM707, a dual antagonist monoclonal antibody (targeting immunoglobulin-like transcript 2/4) in Phase I/II trials for patients with advanced solid tumors. Additionally, the company is developing NGM831 and NGM438, both intended for the treatment of advanced solid tumors. NGM has established significant partnerships, including research, product development, and licensing agreements with Merck Sharp & Dohme Corp. A separate collaboration with Merck & Co., Inc. is dedicated primarily to creating new treatments for pressing unmet patient needs in retinal and cardiovascular-metabolic (CVM) diseases, such as heart failure. Established in 2007, NGM Biopharmaceuticals, Inc. maintains its corporate headquarters in South San Francisco, California.
Prix de l'action
$1.54
Dernière synchronisation: 2024-04-08
Capitalisation boursière
$119.21M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange NGM Biopharmaceuticals, Inc. (NGM)

Catégorie

Healthcare
Historique du prix de l'action pour NGM Biopharmaceuticals, Inc. (NGM)
Prix de clôture le plus élevé : $1.55 le 2024-04-01

Prix de clôture le plus bas : $15.78 le 2019-04-01
Historique du prix de l'action de NGM Biopharmaceuticals, Inc. de 2019 à 2026
Performance annuelle du prix de l'action
Année Performance
2024 86.99%
2023 -84.01%
2022 -71.29%
2021 -34.64%
2020 51.84%
2019 0.00%
Prix de l'action pour des entreprises similaires ou concurrentes
Entreprise Prix de l'action Variation 1a% Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $547.71 38.62%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.04K 58.06%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $145.75 437.43%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $119.73 -14.87%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $770.19 8.98%
CH